EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions

Lara Gallucci Figorelle, Peterson Tiago Galvão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro

Clinical Lymphoma Myeloma and Leukemia · 2024-07 · 24 (7) · 433-445

DOI: 10.1016/j.clml.2024.03.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-07. Verfasst von Lara Gallucci Figorelle und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Proliferação e Diferenciação Celular, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Programa de Pós-graduação em Med…. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of classical Cyclin D1-positive MCL and also in cases without the typical t(11;14) abnormality, making it an important diagnostic marker. MCL's development necessitates secondary genetic changes, including mutations in the ATM, TP53, and NOTCH1 genes, with the TP53 mutation being the only genetic biomarker with established clinical prognostic value. The Mantle Cell Lymphoma International Prognostic Index (MIPI) score, which considers age, performance status, serum LDH levels, and leukocyte count, stratifies patients into risk groups. Histologic variants of MCL, such as classic, blastoid, and pleomorphic, offer additional prognostic information. Recent research highlights new mutations potentially tied to specific populations among MCL patients, suggesting the benefit of personalized management for better predicting outcomes like progression-free survival. This approach could lead to more effective, risk-adapted treatment strategies. However, challenges remain in patient stratification and in developing new therapeutic targets for MCL. This review synthesizes current knowledge on genetic mutations in MCL and their impact on prognosis. It aims to explore the prognostic value of genetic markers related to population traits, emphasizing the importance of tailored molecular medicine in MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellPrecision MedicineHumansPrognosisBiomarkers, TumorMutation

Stichwörter der Autor:innen

Diagnosis, prognosis and treatmentGene mutationHematology oncologyLymphoid neoplasiaPersonalized medicine

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Laboratório de Proliferação e Diferenciação Celular, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Programa de Pós-graduação em Medicina (Anatomia Patológica), Universidade Federal do Rio de Janeiro, R…
  • Programa de Pós-graduação em Ciências Morfológicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Laboratório de Proliferação e Diferenciação Celular, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Programa de Pós-graduação em Medicina (Anatomia Patológica), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Programa de Pós-graduação em Medicina (Anatomia Patológica), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: kcarneiro@histo.ufrj.br.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Gallucci Figorelle, L., Galvão, P. T., de Lima, F. M. R., Marimon, P., Pentagna, N., Milito, C., Schaffel, R., & Carneiro, K. (2024). Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions. Clinical Lymphoma Myeloma and Leukemia, 24(7), 433-445. https://doi.org/10.1016/j.clml.2024.03.010

Vancouver

Gallucci Figorelle L, Galvão PT, de Lima FMR, Marimon P, Pentagna N, Milito C, et al. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions. Clinical Lymphoma Myeloma and Leukemia. 2024;24(7):433-445. doi:10.1016/j.clml.2024.03.010

BibTeX
@article{GallucciFigorelle2024,
  author = {Gallucci Figorelle, Lara and Galvão, Peterson Tiago and de Lima, Felipe Matheus Ribeiro and Marimon, Patricia and Pentagna, Nathalia and Milito, Cristiane and Schaffel, Rony and Carneiro, Katia},
  title = {Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {7},
  pages = {433--445},
  doi = {10.1016/j.clml.2024.03.010}
}
Kostenlos starten →